Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

40.40USD
9 Dec 2016
Change (% chg)

$0.63 (+1.58%)
Prev Close
$39.77
Open
$40.21
Day's High
$40.54
Day's Low
$40.17
Volume
1,438,696
Avg. Vol
2,336,237
52-wk High
$44.50
52-wk Low
$36.81

Latest Key Developments (Source: Significant Developments)

Sanofi reports open market purchase of 450,000 shares of Myokardia
Wednesday, 5 Oct 2016 09:00am EDT 

Sanofi SA : Sanofi reports open market purchase of 450,000 shares Of Myokardia Inc for $15/Share on Oct 3, 2016 .Sanofi's open market purchase of 450,000 shares of myokardia inc made on Oct 3 represents an indirect ownership in Myokardia.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 08:00am EDT 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Sanofi says BARDA grants $43.2 million to Sanofi Pasteur for Zika
Monday, 26 Sep 2016 11:05am EDT 

Sanofi : BARDA grants $43.2 million usd to Sanofi Pasteur for Zika . Beyond funding provided by BARDA for two phase i/ii clinical trials, there is an option for continuing support through phase iii . BARDA and U.S. Department of health and human services has agreed to a proposal to fund manufacture of Zika vaccine for phase ii development ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

U.S. Department of health and human services says BARDA awards funding to Sanofi Pasteur for Zika vaccine
Monday, 26 Sep 2016 10:36am EDT 

U.S. department of health and human services: U.S. Department Of Health And Human Services says contract includes an option for up to an additional $130.45 million to fund phase 3 clinical trials . U.S. Department Of Health And Human Services says BARDA awards funding to speed development of Zika vaccine ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sanofi and Regeneron accepted for priority review by U.S. FDA
Monday, 26 Sep 2016 01:00am EDT 

:Sanofi and Regeneron [REGN.O] announce dupilumab biologics license application accepted for priority review by U.S. FDA.  Full Article

Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi
Friday, 19 Aug 2016 06:28pm EDT 

Zealand Pharma A/S : Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes . Financial guidance for 2016 remains unchanged . A U.S. regulatory decision on iglarlixi is now expected before end of November 2016 .FDA requested updated information on pen delivery device for iglarlixi as part of new drug application, which was submitted by Sanofi.  Full Article

Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources
Friday, 29 Jul 2016 09:40am EDT 

: Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: [MDVN.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Sanofi says Brexit settlement must not impede drug regulation, approval processes
Friday, 29 Jul 2016 01:46am EDT 

Sanofi Chief Executive Olivier Brandicourt tells journalists during a conference call: Any Brexit settlement must not impede new drug regulation, approval process . "For the sake of patients and innovation, we need to ensure that Brexit does not negatively impact the regulatory capacity, the regulatory processes and the time frame for the introduction of new medicine both in the United Kingdom and in Europe, that must remain a priority," he said. Further company coverage: [SASY.PA] (Reporting by Matthias Blamont ; Editing by Andrew Callus) ((matthias.blamont@thomsonreuters.com;)).  Full Article

Sanofi pasteur ships seasonal influenza vaccine doses in U.S.
Tuesday, 26 Jul 2016 08:00am EDT 

Sanofi Pasteur : Ships First Of Its 2016 2017 seasonal influenza vaccine doses in United States .Sanofi pasteur plans to increase its supply to respond to shifting pediatric public health needs.  Full Article

Sanofi India June-qtr profit up about 33 pct
Friday, 22 Jul 2016 06:37am EDT 

Sanofi India Ltd : Says June-quarter net profit 853 million rupees . Says June-quarter net sales 5.65 billion rupees . Says net profit in June-quarter last year was 642 million rupees; net sales was 5.14 billion rupees . Declared interim dividend of 18 rupees per share .  Full Article

Photo

EU regulator accepts Sanofi/Regeneron's Dupixent product for review

PARIS The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday.